Stemedica licenses stem cells to Kalbe Farma

04/26/2013 | Genetic Engineering & Biotechnology News

Stem Cell and Cancer Institute, a unit of PT Kalbe Farma, secured exclusive licensing rights to Stemedica Asia's ischemic-tolerant adult allogeneic mesenchymal and neural stem cells for use in clinical research in the Philippines, Thailand and Indonesia. The deal could be extended to additional countries in Asia.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD